Evidence map›Paper›PMID 37773732›Full record

ArticleCancer biology & therapy2023

Tao Si, Liyin Huang, Ting Liang, Ping Huang, Hongyu Zhang, Mingmin Zhang, Xiaoling Zhou

Open access · goldAbstract read
In one paragraph

Article in Cancer biology & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tao SiDepartment of Oncology, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, China.
Liyin HuangGraduate school, Guangxi University of Chinese Medicine, Nanning, China.
Ting LiangGraduate school, Guangxi University of Chinese Medicine, Nanning, China.
Ping HuangDepartment of Oncology, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, China.
Hongyu ZhangDepartment of Clinical Laboratory, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, China.
Mingmin ZhangDepartment of Oncology, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, China.
Xiaoling ZhouDepartment of Gastroenterology, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, China.ORCID 0000-0002-8063-7399
Guangxi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing number of studies have suggested that traditional Chinese medicine (TCM) plays an essential role in the development and occurrence of liver cancer. However, the function of Ruangan Lidan decoction (RLD) in liver cancer are not yet adequately identified and manifested, which attracted our attention. The key genes related to liver cancer and RLD and the upstream miRNAs of PDK4 were obtained based on bioinformatics analysis, followed by verification of the targeting relationship between miR-9-5p and PDK4. Next, Huh7 cells were treated with RLD to detect cell proliferation, colony formation, migration, invasion, and apoptosis by multiple assays with gain- and loss-of-function experiments. Moreover, subcutaneous transplanted tumor model and lung metastasis model of liver cancer in nude mice were established to further verify the functional role of RLD in liver cancer growth and metastasis via miR-9-5p/PDK4 axis. Bioinformatics analysis found that PDK4 and miR-9-5p were related to liver cancer, and PDK4 may be a downstream regulator of RLD. miR-9-5p could target and inhibit PDK4. In vitro cell experiments demonstrated that RLD suppressed liver cancer cell proliferation, invasion and migration, and promoted apoptosis by inhibiting miR-9-5p expression and promoting PDK4 expression. In vivo animal experiments further confirmed that RLD inhibited liver cancer growth and metastasis via upregulation of miR-9-5p-dependent PDK4. RLD downregulated miR-9-5p and upregulated PDK4 to inhibit the proliferation, migration, invasion, and induce apoptosis, thereby suppressing the growth and metastasis of liver cancer, highlighting a potential novel target for treatment of liver cancer.

Indexed as

Liver NeoplasmsMicroRNAsAnimalsCell Line, TumorDrugs, Chinese HerbalMiceMice, NudeDrugs, Chinese HerballidanMicroRNAsMIRN9 microRNA, mouseLiver cancermiR-9-5pPDK4Ruangan Lidan decoctiontumor growthtumor metastasis

Identifiers

PMID37773732
PMCPMC10543352
OpenAlexW4387166012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.